Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
The business and product range of Ipca and that of Unichem complements each others business and product range
Subscribe To Our Newsletter & Stay Updated
